SEDL / Journals / Journal of Forensic Sciences (JOFS) / Citation Page


Volume 45, Issue 4 (July 2000)

ISSN: 0022-1198
CODEN: JFSCA
Page Count: 3


A Mixed-Drug Intoxication Involving Venlafaxine and Verapamil
Presses, CL
Bexar County Medical Examiner's Office and Forensic Toxicology Laboratory, TX

Kunsman, CM
TX

Kunsman, GW

Garavaglia, JC
Bexar County Medical Examiner's Office and Forensic Toxicology Laboratory, TX

Farley, NJ
Bexar County Medical Examiner's Office and Forensic Toxicology Laboratory, TX

(Received 8 June 1999; accepted 25 October 1999)

Abstract

This case report describes the suicide of a 52-year-old woman whose cause of death was attributed to a mixed-drug intoxication involving venlafaxine and verapamil. Venlafaxine is prescribed for the treatment of depression and should be used with caution in patients with cardiovascular disease. Verapamil is a calcium channel blocker primarily used for treatment of cardiovascular disorders. The following drug concentrations were determined in postmortem fluids: verapamil—3.5 mg/L (femoral blood), 9.4 mg/L (subclavian blood), and 1.0 mg/L (vitreous fluid); norverapamil—1.0 mg/L (femoral blood), 2.1 mg/L (subclavian blood), and 0.20 mg/L (vitreous fluid); verapamil and norverapamil could not be detected in bile or urine due to the high levels of erythromycin present; venlafaxine—6.2 mg/L (femoral blood), 8.6 mg/L (subclavian blood), 5.3 mg/L (vitreous fluid), 54.0 mg/L (bile), and 72.3 mg/L (urine); and O-desmethylvenlafaxine—5.4 mg/L (femoral blood), 8.3 mg/L (subclavian blood), positive (vitreous fluid), 29.2 mg/L (bile), and 9.5 mg/L (urine). The cause of death was determined to be a mixed-drug intoxication resulting from an overdose of verapamil and venlafaxine. The manner of death was determined to be suicide.



Keywords:
forensic science, verapamil, venlafaxine, drug overdose, mixed-drug intoxication

Paper ID: JFS14801J
DOI: 10.1520/JFS14801J
ASTM International is a member of CrossRef.

Author Title A Mixed-Drug Intoxication Involving Venlafaxine and Verapamil Symposium , 0000-00-00 Committee E30